Key result
Fosinopril differs from enalapril and captopril through hydrophilicity, resistance to hepatic breakdown, and extended half-life.
Why the study?
To highlight the role of the interprofessional healthcare team in managing hypertension with fosinopril by detailing its pharmacology, adverse events, eligible patients, and monitoring.
This review highlights the pharmacology, indications, and interprofessional management of fosinopril for cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
Supports fosinopril in HF and HTN algorithms; extends RCT evidence for competitive ACE inhibition across the class.
Angiotensin-converting enzyme (ACE) inhibitors, which have been used to treat cardiovascular diseases for almost thirty years, are related to fosinopril. Both heart failure and hypertension can now be treated with fosinopril, according to the US Food and Drug Administration (FDA). As a competitive inhibitor of ACE, fosinopril prevents angiotensin I from becoming an effective vasoconstrictor, angiotensin II. The following additional ACE inhibitors are authorized in the US: trandolapril, captopril, enalapril, lisinopril, benazepril, quinapril, ramipril, moexipril, and fosinopril. HIV-associated nephropathy, diabetic nephropathy, and acute myocardial infarction are the conditions for which fosinopril is used off-label. The drug's hydrophilicity, resistance to hepatic breakdown, and extended half-life set it apart from enalapril and captopril. This exercise highlights the role of the interprofessional healthcare team in managing hypertension with fosinopril by providing information on the drug's mechanism of action, pharmacology, adverse event profiles, eligible patient categories, and monitoring.
No takes yet. Share an insight, caveat, or question.
G. et al. (2026) conducted a review in Hypertension and heart failure. Fosinopril was evaluated. Fosinopril is an ACE inhibitor used to treat heart failure and hypertension, distinguished from enalapril and captopril by its hydrophilicity, resistance to hepatic breakdown, and extended half-life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: